TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01174940
Drug: extracorporeal photopheresis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC \> 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.~The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:~Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.~After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient.
Study: NCT01356758
Drug: biological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients treated with anti-psoriatic biological agents
Study: NCT03098810
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral syrup zinc sulphate
Study: NCT02279160
Drug: APD811
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02279160
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04139655
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet given at 0.6 mg 1 hour prior to surgery, then 0.6 mg twice daily starting on the night after surgery for 7 days or until discharge from hospital, whichever occurs earlier. For patient under 60kg in body weight, daily dose will be 0.6 mg once daily. Medical and surgical management of the participant will be carried out under each institute's standard clinical practice.
Study: NCT00634751
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
Study: NCT03669614
Drug: Inhaled Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single and multiple ascending doses of inhaled placebo
Study: NCT04402385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomized to placebo daily
Study: NCT04469556
Drug: Folfirinox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy
Study: NCT01287988
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
Study: NCT00442611
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03286634
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO or IV
Study: NCT03286634
Drug: E-coli L-asparaginase
Normalized name: E.COLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IM or IV
Study: NCT03286634
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV, PO or IT
Study: NCT03286634
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IT
Study: NCT03286634
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01511692
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide placebo, injected subcutaneously for 4 weeks
Study: NCT01511692
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
Study: NCT04349072
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02675907
Drug: Intravenous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00655122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
Study: NCT05326906
Drug: PD-1/PD-L1 inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1/PD-L1 inhibitors (the dosage calculation according to dosing instructions)
Study: NCT00405275
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: baseline methotrexate is maintained throughout the study and is not provided by the sponsor
Study: NCT00405275
Drug: Placebo, triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
Study: NCT00608894
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Study: NCT03180294
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: By mouth
Study: NCT03360903
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthetized volunteers will be allowed to wake after injection of saline (placebo control).~Other Names:~* Saline
Study: NCT00362869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium bicarbonate solution
Study: NCT02570711
Drug: ACP-196
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACP-196 capsule
Study: NCT03360903
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg).~Other Names:~* Caffeine citrate
Study: NCT02242695
Drug: Fluomizin vaginal tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vaginal tablet for 6 days and 1 placebo tablet on day 7
Study: NCT00162292
Drug: BMS-582949 and Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01422161
Drug: Botulinum Toxin commonly known as BOTOX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.~There will be 1 treatment cycle during the 9 week study.
Study: NCT01422161
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group will receive a placebo injection.
Study: NCT00144144
Drug: Angiotensin II receptor antagonists, Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03093467
Drug: Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
Study: NCT03622216
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo for Bradanicline
Study: NCT02415595
Drug: TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC
Study: NCT01426724
Drug: Contrast Enhanced Ultrasonography
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
Study: NCT00036231
Drug: RG1068 (Synthetic Human Secretin)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03189537
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule to match Ingavirin capsule
Study: NCT01480791
Drug: Aliskiren vs. hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
Study: NCT02250391
Drug: NPB-06
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days continuous-infusion
Study: NCT02250391
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days continuous-infusion
Study: NCT04388683
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive iNO using the INO pulse device at a dose of 125 mcg/kg IBW/hr (equivalent to approximately 20 ppm). The clinical disease severity will be assessed pre-randomization as the worse of 2 scores measured 2 hours apart. Patients eligible for randomization will be those with scores of 1 or 2 (below), and randomization will be stratified according to score (1 or 2). Study drug will begin within 1 hour of randomization. Beginning on the day following randomization (day 1), we will be calculate clinical score, daily, as the average of 3 measurements taken within 2 hour windows centered at 6AM, 2PM, and 10PM.
Study: NCT01700140
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Study: NCT01060124
Drug: Fentanyl D-trans
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
Study: NCT02631980
Drug: IV iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
Study: NCT04218110
Drug: Isopropyl alcohol & Chlorhexidine Gluconate Antiseptic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antiseptic drug to the inguinal area of the subjects
Study: NCT04218110
Drug: Prevantics 3.15 % / 70 % Swabstick
Normalized name: Prevantics 3.15 % / 70 % Swabstick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of antiseptic drug to the inguinal area of the subjects
Study: NCT01908296
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral
Study: NCT02631980
Drug: IV placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 0.9% saline (250 ml)
Study: NCT02598596
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (1.25 mg/kg, followed by 2.5 mg/kg) oral, daily
Study: NCT02835235
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered daily subcutaneously (s.c., under the skin)
Study: NCT04092686
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet dosed once daily
Study: NCT02264158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00896350
Drug: Standard Care Chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: External beam radiation to the neck and tumor site of head and neck. Concurrent platinum based chemotherapy. External beam boost at discretion of treating physician.
Study: NCT00002842
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
Study: NCT00002842
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
Study: NCT01228838
Drug: NGX-1998
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsaicin topical liquid to be applied for 5 minutes one time only.
Study: NCT01228838
Drug: Placebo Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical liquid to be applied for 5 minutes one time only.
Study: NCT00333021
Drug: GSK576428
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03074409
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-administration of placebo (nasal spray)
Study: NCT05360927
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection
Study: NCT01475877
Drug: Bromfenac
Normalized name: Bromfenac
DrugBank: Bromfenac (DB00963)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromfenac 0.09% 1 drop in study eyes q day
Study: NCT03449758
Drug: Azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Tablet Route of administration: Oral
Study: NCT03449758
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous / Intramuscular
Study: NCT01759628
Drug: H.pylori eradication
Approvals — FDA: no, EMA: no, PMDA: no
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Study: NCT02933788
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
Study: NCT01868594
Drug: Subetta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each Subetta tablet contains a mixture of affinity purified polyclonal antibodies to β-subunit of the rINS (6 mg) and antibodies to eNOS (6 mg) in released-active form produced by the patented technology in accordance with the applicable European Pharmacopeia requirements.~Standard therapy of type I diabetes mellitus + Subetta (1 tablet 4 times a day) for 36 weeks.~Subetta: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study: NCT01868594
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical to Subetta in shape and taste tablet containing exсipients). Standard therapy of type I diabetes mellitus + Placebo (1 tablet 4 times a day) for 36 weeks.~Placebo: oral administration, per 1 intake - 1 tablet (keep in the mouth until complete dissolution, not at mealtime).
Study: NCT00410514
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT00471692
Drug: Ropivicaine
Normalized name: Ropivicaine-Sufentanil Citrate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03306667
Drug: FYU-981
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single dosing
Study: NCT01815944
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01815944
Drug: Dextrose 5%
Normalized name: Dextrose 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01879917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT04381858
Drug: Plasma from COVID-19 convalescent patient
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of 400 ml (2 units) of plasma.~Plasma donated from convalescent patients will be extracted in strict compliance with the following criteria:~* History of a clinical event with symptoms attributed to COVID-19 and a positive PCR test for COVID-19~* Further confirmation of a negative PCR test for COVID-19~* In order to be eligible plasma donors must complete at least 14 days after the last negative PCR in the absence of any symptom attributable to COVID-19 infection~* IgG antibodies for COVID-19 must be confirmed POSITIVE when a qualitative assay is being used~* When quantification of IgG antibodies for COVID-19 is available a title \> 1: 640 will be required for inclusion.~* Apheresis will be used as the only method for plasma extraction.
Study: NCT02016976
Drug: EMLA Analgesic Cream
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02016976
Drug: Dormicum 2.5 mg and Pethidine 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
Study: NCT03231722
Drug: l-leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/sqm iv over 2 hours
Study: NCT00613782
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo injection 0,6.18.30 weeks
Study: NCT03801967
Drug: AZD9977
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive oral dose of AZD9977.
Study: NCT03801967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized participants will receive oral dose of matching placebo.
Study: NCT00629278
Drug: aromatase inhibition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00629278
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00629278
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00629278
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00974142
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifteen patients will receive will receive placebo.
Study: NCT00007592
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01120366
Drug: Tocilizumab plus methotrexate
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
Study: NCT04414995
Drug: Paracetamol injection and Ibuprofen injection
Normalized name: codeine and paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of combination acetaminophen and ibuprofen to reduce morphine requirement inpatient after Total knee arthroplasty
Study: NCT00028483
Drug: cBR96-doxorubicin immunoconjugate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04414995
Drug: Ibuprofen Injection and normal saline
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of ibuprofen and normal saline to reduce morphine requirement inpatient after Total knee arthroplasty
Study: NCT00743444
Drug: AZD3355
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg capsules, oral, 3 single doses
Study: NCT00743444
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules, oral, 3 single doses
Study: NCT01269749
Drug: ATD Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
Study: NCT00092105
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01307319
Drug: BDP HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
Study: NCT01307319
Drug: Placebo nasal aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
Study: NCT02217163
Drug: Carfilzomib, , Cyclophosphamide, Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib is administered intraveneously over 30 minutes. For cycle 1 only, Carfilzomib is administered at 20mg/m2 on Day 1 and 2, dose will be escalated to 36mg/m2 on Day 8,9,15 and 16 of the 28-days cycle. Patients who tolerate the 36mg/m2 dose are kept at this dose for the subsequent cycles on Day 1,2,8,9,15,16 on a 28 days cycle. Cyclophosphamide is given at a fixed dose of 500mg once per week orally, along with dexamethasone which is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib infusion.
Study: NCT03622008
Drug: FEP-TAZ 4 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEP-TAZ 4 g (2 g cefepime + 2 g tazobactam) IV treatments as a q8h infusion (90 min) regimen for 10 days
Study: NCT00806533
Drug: HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for intravenous infusion applied according to SmPC
Study: NCT02204930
Drug: PeproStat
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
Study: NCT01412177
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intratympanic injection of placebo
Study: NCT00008008
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02773381
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration once-daily.
Study: NCT05490017
Drug: KP104
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive KP104 intravenous (IV) dose approximately for 1 hour or subcutaneous (SC) dose.